主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NUVL
#916
Nuvalent, Inc. Class A Common Stock
101.950
0
-0.51%
版块:
基础:
利润货币:
日范围
年范围
日变化
-0.51%
每月变动
-3.57%
6个月变化
+7.37%
年变化
+7.37%
前一天收盘价
102.470
0
Open
101.950
0
Bid
Ask
Low
101.950
0
High
101.950
0
交易量
98
市场
股票
医疗保健
NUVL
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
42.88 M
51.27 M
58.63 M
66.16 M
73.18 M
—
Valuation ratios
Enterprise value
2.69 B
4.69 B
14.29 B
4.27 T
5.49 T
18.24 T
Price to earnings ratio
-8.94
-17.56
-35.07
-19.92
-17.19
-64.88
Price to sales ratio
715.11
—
—
—
—
—
Price to cash flow ratio
-10.37
-22.15
-44.42
-28.09
26.57
-41.76
Price to book ratio
1.46
3.11
6.32
4.86
5.86
9.92
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.16
0.17
0.17
0.23
0.3
0.38
Return on equity %
0.16
0.18
0.18
0.24
0.34
0.43
Return on invested capital %
7 406.59
11.86 K
15 K
14.8 K
4 493.41
2 817.91
Gross margin %
100
—
—
—
—
—
Operating margin %
7 899.48
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
7 982.76
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
33.07
24.54
22.83
20.96
15.27
54.06
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.84
1.31
1.71
2.79
3.79
3.82
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
13.23
9.51
12.36
16.84
18.87
60.93
Net current asset value per share
13.34
9.62
12.48
17.05
19.16
61.79
Tangible book value per share
13.08
9.32
12.03
16.11
17.17
56.09
Working capital per share
12.94
9.23
11.93
16.24
17.9
57.2
Book value per share
13.08
9.32
12.03
16.11
17.17
56.09
新闻
Nuvalent公布第四季度亏损,等待FDA对肺癌药物的决定
Nuvalent reports Q4 loss, awaits FDA decision on lung cancer drug
Drugmakers turn to AI to speed trials, regulatory submissions
Nuvalent Inc股票触及52周高点112.89美元
Nuvalent Inc stock hits 52-week high at 112.89 USD
FDA接受Nuvalent针对ROS1阳性非小细胞肺癌治疗的新药申请
FDA accepts Nuvalent’s NDA for ROS1-positive NSCLC treatment
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock
Nuvalent CSO Pelish sells shares worth $501,752
Nuvalent (NUVL) chief development officer sells $721k in stock
What's Going On With Royalty Pharma Stock Wednesday? - Royalty Pharma (NASDAQ:RPRX)
3 Biotech Stocks With Major 2026 Catalysts